small molecule

SPRYCEL

DASATINIB

Loss of exclusivitySeptember 2026latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	SPRYCEL
Active ingredient	DASATINIB
Strength	140MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2010
Marketing status	RX

Listed patents

Patent	Expires	Type
7491725*PED	September 2026	—
7491725	March 2026	substance, product

Regulatory exclusivity

Code	Expires
PED	June 2026
ODE-225	December 2025

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO